Please login to the form below
How pembrolizumab will change the management of advanced lung cancer
The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf.
Summary/transcript
The Phase III KEYNOTE-024 trial assessed pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) high expressing NSCLC.The primary endpoint was progression-free survival (PFS), which was in favour of pembrolizumab with a prolongation of median PFS from 6 months to 10.3 months. There was also an improvement in overall survival (OS) as well as an improvement in response. Further, the tolerability was in favor of pembrolizumab.
We talked Dr Martin Reck about the trial. He explains that “this data will completely change our management of patients with advanced lung cancer”. In light of these findings, it is important to screen patients for PD-L1 expression and for those patients with high PD-L1 expression, pembrolizumab will be an option for first-line therapy.
If you would like to discover how we can leverage our network of relationships and understanding of the oncology landscape and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact Stephen Dunn or Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.
Company Details
Brandcast Health
+44 (0)20 7291 5070
Address:
16-17 Little Portland Street
London
W1W 8BP
Latest content on this profile
- Ansar Jawair discusses precision medicines - what they are, where we are today and their future
- Ansar Jawair, Founder and CEO of Precision Medicines Ltd, tells us about his talk on precision medicines, what they are, where we are today, the future and some of the challenges involved in their implementation to patients. Precision medicines are matched to patients using biomarkers, enabling to target the specific drivers of various cancers. Major advances have already been made in this field, treating a range of cancers. Some of the major challenges include working with the complexities in different countries, trying to establish diagnostic testing, for enabling precision medicine. He mentions how we are moving towards an era of delivering personalised treatments that are matched to the individual patient. Furthermore, through advances in precision medicines and in diagnostic testing, we are seeing earlier detection of disease and identification of risk factors, allowing for preventative measures.
Brandcast Health
- Oradit Ido talks about the Unique Israeli Entrepreneurial Ecosystem
- Orado provides an overview of why she believes Israel is unique in its approach to innovation. With a history of overcoming challenges, a people who pride themselves on their chutzpe (audaciousness), and a fast paced culture, she explains why she thinks Israel provides a perfect ecosystem for innovation and entrepreneurship. She explains that within medicine and healthcare, there is a need for strategic support and engagement, and as an example of how the government is supporting this she provides an overview of the Ministry of Health challenge tender programme.
Brandcast Health
- Acute leukaemia patients get new online information centre that will help them get the best possible care
- A unique collaboration between some of the world's leading leukaemia experts and the patient community in the UK and across Europe has resulted in the development of a one-of-a-kind educational resource centre that provides acute leukaemia patients with the support they need, when they need it most.
It is the first time that such a comprehensive medical information video resource has been gathered together in this format and comes at a time when cancer patients and caregivers are advocating for a bigger say in decisions about their individual treatment regimens.
Brandcast Health
- Aubrey De Grey provides a summary of his goal of combating ageing
- Aubrey believes ageing is a serious issue, not only because people die of old age, but because it causes suffering. He discusses the fact that many diseases including chronic cancer, are the result of ageing and that by tackling ageing of cells, we can address many of the issues associated with poor health. To find out more about Aubrey and the SENS Research Foundation visit: http://www.sens.org/
Brandcast Health
- Oradit Ido talks about the Unique Israeli Entrepreneurial Ecosystem
- Orado provides an overview of why she believes Israel is unique in its approach to innovation. With a history of overcoming challenges, a people who pride themselves on their chutzpe (audaciousness), and a fast paced culture, she explains why she thinks Israel provides a perfect ecosystem for innovation and entrepreneurship. She explains that within medicine and healthcare, there is a need for strategic support and engagement, and as an example of how the government is supporting this she provides an overview of the Ministry of Health challenge tender programme.
Brandcast Health
- HaemOncCam #Haem2016
Brandcast Health
